Baricitinib in the Treatment of Patients with COVID-19: A Review of International Data and Analysis of Clinical Results in the Russian Population

The effects of baricitinib, a selective reversible inhibitor of Janus kinase 1 and 2, in the treatment of COVID-19 are associated with different aspects of pathogenesis — inhibition of viral endocytosis, reduction of excessive inflammatory response, and mitigation of vascular and pulmonary damage, whic...

詳細記述

書誌詳細

出版年:	Антибиотики и Химиотерапия
主要な著者:	А. I. Zagrebneva, Е. А. Baryakh, Е. I. Zhelnova, N. G. Poteshkina, I. Р. Beloglazova, Z. Yu. Mutovina, I. V. Samsonova, Е. А. Kovalevskaya, V. V. Parshin, V. V. Pshenichnikova, D S. Fomina, Т. S. Kruglova, М. А. Lysenko, М. А. Dranitsyna
フォーマット:	論文
言語:	ロシア語
出版事項:	LLC "Publishing House OKI" 2021-05-01
主題:	covid-19, pneumonia, therapy, baricitinib
オンライン･アクセス:	https://www.antibiotics-chemotherapy.ru/jour/article/view/793